June 26 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA ANNOUNCES PUBLICATION OF IPH4102 PHASE I CLINICAL TRIAL RESULTS FOR CTCL IN THE LANCET ONCOLOGY.AN UPDATE ON OUTCOME OF FIRST STAGE OF MF AND PTCL COHORTS IS EXPECTED IN SECOND HALF OF 2020.SÉZARY SYNDROME ARM OF STUDY COULD ENABLE REGISTRATION OF IPH4102 IN THIS INDICATION.
Full Article
June 12 (Reuters) - Innate Pharma SA ::INNATE PHARMA ANNOUNCES INTENTION TO CONDUCT A REGISTERED OFFERING IN UNITED STATES.TIMING, NUMBER OF NEW ORDINARY SHARES AND ADSS TO BE ISSUED AND PRICE OF ORDINARY SHARES AND ADSS TO BE ISSUED IN PROPOSED PUBLIC OFFERING AND PRIVATE PLACEMENT HAVE NOT YET BEEN DETERMINED.SIMULTANEOUSLY WITH PUBLIC OFFERING IN UNITED STATES, COMPANY PLANS TO CONDUCT PRIVATE PLACEMENT OF ITS ORDINARY SHARES OUTSIDE OF UNITED STATES, PRIMARILY IN EUROPE, INCLUDING IN FRANCE.
Full Article
June 12 (Reuters) - Innate Pharma SA ::REG-INNATE PHARMA TO PRESENT IPH4102 “TELLOMAK” CLINICAL TRIAL DESIGN AND PRECLINICAL PTCL DATA AT THE 2019 ICML.NEW PRECLINICAL DATA SHOW IPH4102 AND CHEMOTHERAPY COMBINATION ENHANCES KIR3DL2 EXPRESSION AND HAS SUPERIOR ANTI-TUMOR ACTIVITY.NEW PRECLINICAL DATA SHOW IPH4102, CHEMOTHERAPY COMBINATION PROVIDES RATIONALE FOR PERIPHERAL T-CELL LYMPHOMA COHORT.
Full Article
April 1 (Reuters) - Innate Pharma SA ::* Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting.* Next generation immunotherapies has been presented in a conference session by Pr. Eric Vivier, Chief Scientific Officer, at the American Association for Cancer Research (AACR) Annual Meeting held from March 29–April 3, in Atlanta..* Also shared data from multi-specific NK-cell engager technology that highlight a new generation of molecules for fighting cancers. .
Full Article
March 20 (Reuters) - INNATE PHARMA SA ::FY NET PROFIT OF EUR 3 MILLION (NOT LOSS OF EUR 3.0 MILLION) VERSUS LOSS OF EUR 41.7 MILLION YEAR AGO.2018 FINANCIAL RESULTS AND BUSINESS UPDATE: LANDMARK DEAL WITH ASTRAZENECA TO SUPPORT TRANSITION INTO A FULLY INTEGRATED ONCOLOGY-FOCUSED BIOTECH, STRONG CLINICAL PROGRESS IN LEAD ASSETS.REVENUE AND OTHER INCOME AMOUNTED TO EUR 94.0M (EUR 36.2M IN 2017).FY OPERATING EXPENSES AMOUNTED TO EUR 87.7M (EUR 76.0M IN 2017), IN WHICH APPROXIMATELY 79% DEDICATED TO RESEARCH AND DEVELOPMENT.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTING TO €202.7M (MILLION EUROS) AS OF DECEMBER 31, 2018 (€176.6M AS OF DECEMBER 31, 2017), INCLUDING NON-CURRENT FINANCIAL INSTRUMENTS (€35.2M).
Full Article
Feb 12 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA ANNOUNCES APPOINTMENT OF LAURE-HÉLÈNE MERCIER TO THE EXECUTIVE BOARD.
Full Article
Jan 29 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME.FTD IS BASED ON THE EVALUATION OF PHASE I RESULTS DEMONSTRATING STRONG CLINICAL ACTIVITY, FAVORABLE SAFETY AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE.TELLOMAK, A GLOBAL, MULTI-COHORT, PHASE II STUDY EVALUATING POTENTIAL OF IPH4102 IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS, WILL BE INITIATED IN H1 2019.
Full Article
Nov 30 (Reuters) - INNATE PHARMA SA ::PUBLICATION OF MONALIZUMAB RESEARCH IN "CELL" JOURNAL.PUBLICATION REPORTS THAT MONALIZUMAB STIMULATES SIMULTANEOUSLY ANTI-TUMOR ACTIVITY OF NK CELLS AND T CELLS.COMBINATION OF THEIR NKG2A BLOCKING ANTIBODY WITH A PD-L1 BLOCKING ANTIBODY PROVIDES AN ADDITIVE EFFECT TOWARDS ACTIVATION OF AN ANTI-TUMOR IMMUNITY.MONALIZUMAB CETUXIMAB COMBINATION IS WELL TOLERATED AND PROVIDES ENCOURAGING EFFICACY RESULTS.
Full Article
Nov 15 (Reuters) - INNATE PHARMA SA ::END-Q3 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS EUR 131.7 MILLION.Q3 REVENUE IFRS 15 EUR 5.6 MILLION VERSUS EUR 5.8 MILLION RESTATED YEAR AGO.RECRUITMENT OF THE FIRST PATIENT IN PHASE I STUDY EVALUATING IPH5401 IN ONCOLOGY.TOLERANCE DATA FOR IPH5401 EXPECTED IN H2 OF 2019.PHASE II PROGRAM TESTING OF IPH4102 FOR MULTIPLE TYPES OF T-TYPE LYMPHOMA WILL BE INITIATED IN H1 OF 2019.
Full Article
Oct 23 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA STRENGTHENS AND EXPANDS ITS ONCOLOGY DEVELOPMENT COLLABORATION WITH ASTRAZENECA.INNATE PHARMA ACQUIRES US AND EU RIGHTS TO COMMERCIALIZE LUMOXITI TO BECOME A FULLY-INTEGRATED ONCOLOGY-FOCUSED BIOTECH.ASTRAZENECA OBTAINS FULL ONCOLOGY RIGHTS TO MONALIZUMAB.ASTRAZENECA GAINS ACCESS TO INNATE PHARMA'S ANTI-CD39 MONOCLONAL ANTIBODY, IPH5201, PLUS FOUR ADDITIONAL IMMUNO-ONCOLOGY MOLECULES.ASTRAZENECA TO PURCHASE NEWLY-ISSUED EQUITY STAKE OF 9.8% IN INNATE PHARMA.
Full Article
Earnings vs. 
Estimates